Loading
Post Stroke Depression / Zuranolone · Phase 2 Trial
ClinicalTrials.gov · September 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for zuranolone in post-stroke depression. No results have been posted in this registry record. The study is actively recruiting and aims to evaluate safety, tolerability, and treatment efficacy in a very small open-label cohort.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Post Stroke Depression; age from 21 Years; to 65 Years. Intervention: Zuranolone. n = 6. 1 site: United States.
This is a Phase 2 trial registration for zuranolone in post-stroke depression. No results have been posted in this registry record. The study is actively recruiting and aims to evaluate safety, tolerability, and treatment efficacy in a very small open-label cohort.
This is a trial registration only; no results, efficacy data, or adverse event outcomes are reported.
No guidance can be derived at this stage. Clinicians should await publication of results to assess whether zuranolone merits consideration in post-stroke depression.
This is an ongoing Phase 2 trial registration with no posted results; the study is recruiting and designed to evaluate safety, tolerability, and efficacy of zuranolone in a very small population (n=6) with post-stroke depression.
As stated by the source record.
Quoted from the source exactly as published.
No guidance can be derived at this stage. Clinicians should await publication of results to assess whether zuranolone merits consideration in post-stroke depression.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06759558). This is a study registration, not published results. Lead sponsor: Duke University. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 6 participants (ESTIMATED). Conditions: Post Stroke Depression. Interventions: DRUG: Zuranolone. Primary outcome measures: Number of participants with treatment emergent adverse events (TEAEs) after starting zuranolone , 90 days; Severity of suicidal ideation after starting zuranolone as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) , 90 Days; Severity of somnolence after starting zuranolone as measured by the Epworth Sleepiness Scale (ESS) , 90 Days. Brief summary: The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are: * Is zuranolone safe to take by participants who have moderate to severe post-stroke depression? * Is zuranolone well-tolerated by participants who have moderate to severe post-stroke depression? * Does zuranolone treat moderate to severe post-stroke depression? The study will enroll six participants. All participants will be given 50 mg of zuranolone for 14 days. Participants will be asked to provide blood samples, complete some questionnaires including those related to mood and a cognitive assessment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.